None of the 29 investors followed here reported a position in ADTX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ADTX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 22, 2026 | Takeover Time 2026 L.L.CBeneficial Owner of more than 10% of a Class of Security | Sale at price 0.04 per share. | 3.42M | $142.63K |
| Jun 21, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 0.02 per share. | 5.12M | $92.17K |
| Jun 17, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Purchase at price 0.01 per share. | 7.34M | $73.40K |
| Jun 16, 2026 | Drw Holdings, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.00 per share. | 126.8K | $558 |
| Jun 15, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 0.01 per share. | 3.13M | $40.72K |
| Jun 11, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Purchase at price 0.01 per share. | 4.25M | $54.01K |
| Jun 10, 2026 | Bank Of America CorporationBeneficial Owner of more than 10% of a Class of Security | Purchase at price 0.01 per share. | 7 | — |
| Jun 10, 2026 | Bank Of America CorporationBeneficial Owner of more than 10% of a Class of Security | Sale at price 0.01 per share. | 15 | — |
| Jun 10, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 0.01 per share. | 2.83M | $39.67K |
| Jun 9, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Purchase at price 0.02 - 0.05 per share. | 2.15M | $83.53K |
| Jun 8, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 0.03 per share. | 878.7K | $29.00K |
| Jun 8, 2026 | Gong SandieBeneficial Owner of more than 10% of a Class of Security | Sale at price 0.03 per share. | 100K | $2.89K |
| Jun 4, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 0.06 per share. | 735.5K | $45.60K |
| Jun 3, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Purchase at price 0.08 per share. | 843.6K | $64.11K |
| Apr 23, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 0.01 per share. | 33.2K | $350 |
| Apr 21, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 0.30 per share. | 12K | $3.60K |
| Apr 20, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Purchase at price 0.33 per share. | 72.9K | $24.06K |
| Dec 16, 2025 | Brady Brian MichaelDirector | Sale at price 1.75 per share. | 1 | $2 |
| Nov 24, 2025 | Pankovcin Corinne DOfficer | Sale at price 3.20 per share. | 1 | $3 |
| Oct 15, 2024 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 1.17 per share. | 25.5K | $29.88K |
No analyst coverage for this instrument.
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes. In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantifies the level of the 3.4kb mtDNA deletion; and Mitomic endometriosis test, a blood-based assay that quantifies the level of one or more mtDNA deletions. Further, it offers Adivir for commercial development of products to address significant unmet needs in infectious disease and population health; and Adifem address critical unmet needs in women health. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
No recent headlines.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.3 | -44.0 | -73.2 | -80.1 | -97.8 | -94.9 | -50.0 | 166.7 | -50.0 | -25.0 | −100.0% | ||
| 2025 | -43.7 | -42.1 | -71.1 | -50.7 | -33.0 | -13.5 | -14.8 | -5.5 | -27.0 | -92.2 | -43.0 | -78.0 | −100.0% |
| 2024 | -41.9 | -9.4 | -2.6 | -29.1 | -20.3 | -28.6 | -13.1 | -46.1 | -83.3 | -87.0 | -33.3 | -48.6 | −99.9% |
| 2023 | 17.7 | -16.9 | -19.4 | -35.6 | 3.9 | -26.2 | -11.6 | 245.5 | -77.3 | -46.0 | -41.2 | 67.0 | −85.6% |
| 2022 | -17.7 | -16.6 | 24.2 | -30.0 | -11.6 | -49.5 | 10.5 | -3.2 | -55.7 | -20.6 | -33.5 | -35.5 | −95.7% |
| 2021 | 79.3 | -18.8 | -15.8 | 12.2 | -1.7 | -7.8 | -17.4 | -11.7 | -10.6 | -3.6 | -28.2 | -54.2 | −74.2% |
| 2020 | -25.7 | -14.6 | -39.3 | -1.5 | 6.3 | 2.0 | −58.9% |